Panbela Therapeutics, Inc. (PBLA)

Market Cap	971.00 -98.2%
Revenue (ttm)	n/a
Net Income	-37.05M
EPS	-11.31
Shares Out	4.85M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	348
Open	0.0002
Previous Close	n/a
Day's Range	0.0002 - 0.0002
52-Week Range	0.000001 - 2.5000
Beta	32.47
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Panbela Therapeutics

Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activate...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 8
• Stock Exchange: OTCMKTS
• Ticker Symbol: PBLA

Financial Performance

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Nov 9, 2026

Data Sources Report a data error